Last update May 25, 2018
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
G03CA09 is Promestriene in ATC Code/s.Is written in other languages:
G03CA09 belongs to this group or family:
Main tradenames from several countries containing G03CA09 in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Estrogen derived from estradiol with trophic effects on vaginal mucosa. Indicated in vulvo-vaginal atrophy
Topical use once or twice daily.
Up to the last update date we did not find published data on your excretion in breastmilk.
The low plasma absorption through the vaginal mucosa (Santos 2010), less than 1% (AEMPS 2018), makes the passage of a significant amount to breast milk unlikely.
Negative absorption has been demonstrated through the infant foreskin (Salmon 2013) and the absence of hormonal systemic effects in women (Santos 2010, Wolff 1982) with the topical use of promestriene.
Non-hormonal lubricants (cream, jelly or ovules) are preferred agents for treatment of vaginal dryness due to hypo-estrogenic stimulation than those estrogenic-containing topical agents.